Patents Assigned to Genspera, Inc.
-
Publication number: 20160347706Abstract: Provided herein are methods of making the compound of Formula I: and certain intermediates involved in such process.Type: ApplicationFiled: August 9, 2016Publication date: December 1, 2016Applicant: Genspera, Inc.Inventors: John K. Lynch, Jeff Hutchison, Xiong Fu, Kevin Kunnen
-
Publication number: 20160347730Abstract: Provided herein are methods of making the compound of Formula I: and certain intermediates involved in such process.Type: ApplicationFiled: August 9, 2016Publication date: December 1, 2016Applicant: Genspera, Inc.Inventors: John K. Lynch, Jeff Hutchison, Xiong Fu, Kevin Kunnen
-
Patent number: 9446141Abstract: Provided herein are methods of making the compound of Formula I: and certain intermediates involved in such process.Type: GrantFiled: March 14, 2014Date of Patent: September 20, 2016Assignee: GenSpera, Inc.Inventors: John K Lynch, Jeff Hutchison, Xiong Fu, Kevin Kunnen
-
Publication number: 20160030589Abstract: Provided is a method for making the compound of Formula 1: Various compounds utilized in that method are also provided, as are methods of making those compounds. Also provided is a compound having the formula XO—CO—(CH2)nNH2, where n is an integer greater than 2. A method of making that compound is additionally provided. Further provided is a method of making a prodrug of a bioactive compound.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicant: Genspera, Inc.Inventors: John K Lynch, Jeff Hutchison, Xiong Fu, Kevin Kunnen
-
Publication number: 20150265572Abstract: Provided herein are therapeutic prodrug compositions which may be delivered to a patient via an injectable emulsion, comprising a therapeutic drug linked to a peptide that is efficiently and specifically cleaved by a selected protease associated with a cell proliferative disorder, including cancer cells, for example, prostate, liver or breast cancer cells, in a patient. Also provided herein are methods of treating cell proliferative disorders, including cancers, with the therapeutic prodrug compositions.Type: ApplicationFiled: October 14, 2013Publication date: September 24, 2015Applicant: GENSPERA, INC.Inventors: Andrew X Chen, Yali Tsai
-
Publication number: 20150238460Abstract: Provided herein are methods of treating subjects having tumors. For example, the invention relates to a method for treating subjects having hepatocellular carcinoma by administering an effective amount of a therapeutic prodrug.Type: ApplicationFiled: August 23, 2013Publication date: August 27, 2015Applicant: GENSPERA, INC.Inventor: Devalingam Mahalingam
-
Patent number: 8822406Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.Type: GrantFiled: May 31, 2012Date of Patent: September 2, 2014Assignee: GenSpera, Inc.Inventors: Samuel R. Denmeade, John T. Isaacs
-
Patent number: 8669231Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.Type: GrantFiled: January 10, 2011Date of Patent: March 11, 2014Assignee: GenSpera, Inc.Inventors: Samuel R. Denmeade, John Tod Isaacs, Hans Lilja
-
Patent number: 7906477Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.Type: GrantFiled: November 18, 2003Date of Patent: March 15, 2011Assignee: Genspera, Inc.Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
-
Patent number: 7767648Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic drugs are activated and exert their toxicity. Sesquiterpene-?-lactones form part of the prodrugs, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.Type: GrantFiled: November 25, 2008Date of Patent: August 3, 2010Assignee: Genspera, Inc.Inventors: John Tod Isaacs, Samuel R. Denmeade
-
Patent number: 7635682Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1);Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.Type: GrantFiled: January 6, 2006Date of Patent: December 22, 2009Assignee: Genspera, Inc.Inventors: Samuel R. Denmeade, John T. Isaacs
-
Publication number: 20090163426Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic drugs are activated and exert their toxicity. Sesquiterpene-?-lactones form part of the prodrugs, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.Type: ApplicationFiled: November 25, 2008Publication date: June 25, 2009Applicant: GENSPERA, INC.Inventors: John Todd Isaacs, Samuel R. Denmeade
-
Patent number: 7468354Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic drug are activated and exert their toxicity. Sesquiterpene-?-lactones form part of the prodrugs, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.Type: GrantFiled: November 30, 2001Date of Patent: December 23, 2008Assignee: Genspera, Inc.Inventors: John T. Isaacs, Samuel R. Denmeade
-
Publication number: 20080247950Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.Type: ApplicationFiled: March 15, 2007Publication date: October 9, 2008Applicant: Genspera, Inc.Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja